Ya.Z. Plieva1, D.V. Rogozhin2, E.S. Gershtein3, I.V. Babkina4, K.I. Jordania5

1–5 N.N. Blokhin National Medical Research Center of Oncology Ministry of Healthcare of the Russian Federation (Moscow, Russia)

1 yana-plieva@mail.ru, 2 pathol.777@mail.ru, 3 esgershtein@gmail.com, 4 docbabkina@rambler.ru, 5 kiazo2@yandex.ru

Ovarian cancer (OC) is one of the types of malignant tumors, which in most cases is detected at a late stage. The initial stages of oncogenesis are often asymptomatic, in 75% of cases the disease is diagnosed at stages 3-4, when it is not always possible to achieve the desired therapeutic result. Early detection of ovarian cancer allows one to expect a complete cure. The etiology of ovarian cancer is unknown, and its pathogenesis has not been sufficiently studied. Prospects in the diagnosis and treatment of ovarian cancer are associated with the main components of the mitogenic system of insulin-like growth factors and their transport proteins in the blood (IGF/IGFBP). The aim of the work is a comparative analysis of the content of IGF-I in the blood serum and tumor lysates of patients with ovarian cancer, taking into account the key factors characterizing the disease, and in healthy women. Reliably higher median of IGF-I was found in the blood serum of patients with ovarian cancer, compared to healthy women, while the marker level was not associated with age, reproductive status, concomitant somatic and gynecological diseases. It was noted that serum IGF-I levels were not associated with the stage, histological structure of the tumor, the presence of metastases in the greater omentum and liver, the presence of ascites, or with CA-125 levels. However, the IGF-I content in the blood serum was statistically significantly higher in patients with poorly differentiated OC and was inversely associated with the marker level in tumor lysates. No relationship was found between the IGF-I content in tumor lysates and the age of patients with OC, reproductive status, or concomitant gynecological diseases. IGF-I levels in the tumor were significantly lower at stages Ia-Ib than at stages IIIc-IV. The IGF-I content was significantly higher in serous and clear cell OC lysates than in mucinous OC. We believe that the determination of IGF-I in the blood serum and tumor lysates of OC patients can serve as an additional factor characterizing the biological features of the neoplasm. Further observations of patients will allow us to determine the role of the above growth factor in assessing sensitivity to drugs and prognosis of the disease.

Plieva Ya.Z., Rogozhin D.V., Gershtein E.S., Babkina I.V., Jordania K.I. IGF-I content in blood serum and tumor tissue of ovarian cancer patients. Technologies of Living Systems. 2025. V. 22. № 3. Р. 34-43. DOI: https://doi.org/10.18127/j20700997-202503-04
(In Russian).

1. Cabasag C.J., Fagan P.J., Ferlay J. et al. Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020. Int. J. Cancer. 2022. V. 151(9). P. 1535–1541. DOI: 10.1002/ijc.34002
2. Malvezzi M., Carioli G., Rodriguez T. et al. Global trends and predictions in ovarian cancer mortality. Ann. Oncol. 2016.
   V. 27(11). P. 2017–2025. DOI: 10.1093/annonc/mdw306
3. Rak yaichnikov: fundamental'nye i klinicheskie issledovaniya : monografiya. Pod red. N.E. Kushlinskogo, L.F. Gulyaevoj, N.A. Ognerubova, I.S. Stilidi. M.: Blok-Print. 2021. 752s. (in Russian).
4. Siegel R.L., Giaquinto A.N., Jemal A. Cancer statistics, 2024. CA Cancer J. Clin. 2024. V. 74(1). P. 12–49. DOI: 10.3322/caac.21820
5. Karelina O.B., Artymuk N.V., Fetisova T.I. Faktory riska raka yaichnika i vozmozhnye preventivnye strategii. Fun-damental'naya i klinicheskaya medicina. 2018. T. 3. № 3. S. 91–96. (in Russian).
6. Zhordania K.I., Payanidi YU.G., Loginov V.I. i dr. Sinhronnye endometrioidnye opuholi matki i yaichnikov. Slozhnosti interpretacii. Problemy reprodukcii. 2018. T. 24. № 4. S. 66–70. DOI: 10.17116/repro20182404166 (in Russian).
7. Gulyaeva L.V. Nereshennye voprosy kancerogeneza yaichnikov. V knige «Rak yaichnikov: fundamental'nye i klinicheskie issledovaniya»: monografiya. Pod red. N.E. Kushlinskogo, L.F. Gulyaevoj, N.A. Ognerubova, I.S. Stilidi. M.: Blok-Print. 2021. S. 147–170. (in Russian).
8. Loginov V.I., Tereshkina I.V., Kushlinskij D.N. i dr. Analiz urovnej metilirovaniya genov mikroRNK v opuholi i meta-stazah s uchetom koncentracij VEGF v plazme krovi bol'nyh rakom yaichnikov. Tekhnologii zhivyh sistem. 2023. T. 20. № 3. S. 5–17. DOI: 10.18127/j20700997-202301-01 (in Russian).
9. Brokaw J., Katsaros D., Wiley A. et al. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors. 2007. V. 25. № 5. P. 346–354. DOI: 10.1080/08977190701838402
10. Forbes B.E., Blyth A.J., Wit J.M. Disorders of IGFs and IGF-1R signaling pathways. Mol. Cell Endocrinol. 2020. V. 518. Article 111035. DOI: 10.1016/j.mce.2020.111035
11. Zhang Y., Gao C., Cao F. et al. Pan-Cancer Analysis of IGF-1 and IGF-1R as Potential Prognostic Biomarkers and Immunotherapy Targets. Front. Oncol. 2021. V. 11. Article 755341. DOI: 10.3389/fonc.2021.755341
12. Ahmed A.I., Dowidar M.F., Negm A.F. et al. Bone marrow mesenchymal stem cells expressing Neat-1, Hotair-1, miR-21, miR-644, and miR-144 subsided cyclophosphamide-induced ovarian insufficiency by remodeling the IGF-1-kisspeptin system, ovarian apoptosis, and angiogenesis. Ovarian Res. 2024. V. 17. № 1. P. 184. DOI: 10.1186/s13048-024-01498-x
13. Li X., Lin S., Yang X. et al. When IGF-1 Meets Metabolic Inflammation and Polycystic Ovary Syndrome. Int. Immunopharmacol. 2024. V. 138. Article 112529. DOI: 10.1016/j.intimp.2024.112529
14. Fanti M., Longo V.D. Nutrition, GH/IGF-1 signaling, and cancer. Endocr. Relat. Cancer. 2024. V. 31. № 11. Article e230048. DOI: 10.1530/ERC-23-0048
15. Peeters P.H., Lukanova A., Allen N. et al. Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr. Relat. Cancer 2007. V. 14. № 1. P. 81–90.
16. Tworoger S.S., Lee I.M., Buring J.E. et al. Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts. Cancer Epidemiol. Biomarkers Prev. 2007. V. 16. № 8. P. 1691–1695.
17. Monson K.R., Goldberg M., Wu H.C. et al. Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort. Breast Cancer Res. 2020. V. 22. № 1. P. 109. DOI: 10.1186/s13058-020-01352-0
18. Weroha S.J., Haluska P. The insulin-like growth factor system in cancer. Endocrinol. Metab. Clin. North Am. 2012. V. 41. № 2. P. 335–350. DOI: 10.1016/j.ecl.2012.04.014
19. Shao M., Hollar S., Chambliss D. et al. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. Mol. Cancer Ther. 2012. V. 11. № 7. P. 1576–1586. DOI: 10.1158/1535-7163.MCT-11-0961
20. Jia Y., Zhang Y., Qiao C. et al. IGF-1R and ErbB3/HER3 contribute to enhanced proliferation and carcinogenesis in trastuzumab-resistant ovarian cancer model. Biochem. Biophys. Res. Commun. 2013. V. 436. № 4. P. 740–755. DOI: 10.1016/j.bbrc.2013.06.030
21. Gershtein E.S., Korotkova E.A., Shcherbakov A.M. et al. Matrix metalloproteinases 7 and 9 and their types 1 and 4 tissue inhibitors in tumors and plasma of patients with colorectal cancer. Bull. Exp. Biol. Med. 2007. V. 143. № 4. P. 459–462. DOI: 10.1007/s10517-007-0156-1